Science Explorer Back to mapMap
Discussion
Researcher · Simcere Pharmaceutical (China) · China

Ningning Luo

Ningning Luo publishes mostly in Pulmonary and Respiratory Medicine, Oncology and Cancer Research, on topics such as Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics and Glioma Diagnosis and Treatment.

ORCID 0000-0002-1991-1168 OpenAlex
World rank
#4,522,574
of 7,710,434 ranked researchers
Rank in China
#690,858
of 978,568
Works
71
Citations
282
Citations per work
4.0
h-index
8
i10-index 6Top 64% in Pulmonary and Respiratory Medicine
Ningning Luo

What does Ningning Luo research?

Ningning Luo's work is mostly in Medicine (48%), Biochemistry, Genetics and Molecular Biology (26%).

Health Sciences: 34 works · 47.7% of their workMedicine: 34 works · 47.7% of their workPulmonary and Respiratory Medicine: 16 works · 22.3% of their workOncology: 12 works · 16.8% of their workGenetics: 6 works · 8.6% of their workLife Sciences: 19 works · 26.4% of their workBiochemistry, Genetics and Molecular Biology: 19 works · 26.4% of their workCancer Research: 9 works · 12.7% of their workMolecular Biology: 7 works · 9.6% of their workGenetics: 3 works · 4.1% of their workEverything else: 18 works · 25.9% of their workTHEIR WORKNingning Luo71works
Life Sciences26%Health Sciences48%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine3447.7%
    1. Biochemistry, Genetics and Molecular Biology1926.4%
  3. Everything else1825.9%
  1. 1Pulmonary and Respiratory Medicine22% of their works
  2. 2Oncology17% of their works
  3. 3Cancer Research13% of their works
  4. 4Molecular Biology10% of their works
  5. 5Genetics9% of their works
  6. 6Genetics4% of their works

Research topics

Which keywords describe Ningning Luo's research?

The keywords of their largest research topics: Targeted Therapy, Clinical Trials, ALK Inhibitors, EGFR Mutations, Genomic Instability, Immunotherapy, Cancer Genomics and Mutational Signatures.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 22 words, with their numbers
  1. Targeted Therapy523 topics
  2. Clinical Trials322 topics
  3. ALK Inhibitors251 topic
  4. EGFR Mutations251 topic
  5. Genomic Instability252 topics
  6. Immunotherapy242 topics
  7. Cancer Genomics201 topic
  8. Mutational Signatures201 topic
  9. Glioblastoma171 topic
  10. Temozolomide171 topic
  11. Cancer Risk122 topics
  12. Genetic Testing122 topics
  13. Immune Checkpoint Blockade101 topic
  14. PD-1 and PD-L1101 topic
  15. Genomic Profiles71 topic
  16. Microsatellite Instability71 topic
  17. Molecular Characterization71 topic
  18. Small-Cell Lung Cancer71 topic
  19. BRCA151 topic
  20. BRCA251 topic
  21. DNA Damage51 topic
  22. Repair51 topic

Where does Ningning Luo work?

Ningning Luo's main affiliation in the publication record is Simcere Pharmaceutical (China), China.

How many publications and citations does Ningning Luo have?

OpenAlex counts 71 works and 282 citations for Ningning Luo, an h-index of 8, ranking #4,522,574 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Other researchers named Ningning Luo

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Ningning Luo. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.